Livzon Pharma's YJH-012 injection receives clinical trial approval

Livzon Pharmaceutical Group Co., Ltd. [SZSE:000513] announced that it has received approval from the National Medical Products Administration to commence clinical trials for YJH-012 injection, classified as a Class 1 chemical drug, for the treatment of gout. Developed in collaboration with Ubigene (Hangzhou) Biosciences, the YJH-012 injection utilizes siRNA technology aiming for long-term gene-level inhibition of uric acid production. As of the announcement date, Livzon has invested approximately CNY2,573,860 in research and development for the YJH-012 injection. There are currently no similar small nucleic acid products approved for gout treatment in China.